\
&
Contact us
\
&
Contact us
Starts in 3 hours ago
LocationOnline
ProgrammesThe online Brokerage Event for the new European Research Area or ERA call 2026 is organised by NCP_WIDERA.NET, the network of National Contact Points for Widening Participation and Strengthening the European Research Area (WIDERA). The event will focus on the ERA 2026 call topics specified in the Horizon Europe WIDERA Work Programme for 2026-2027 (draft version available here).
The Brokerage Event will provide an opportunity for participants to engage in matchmaking with potential ERA call 2026 participants and stakeholders through pre-arranged bilateral meetings. This aims to identify possible collaborations and streamline the establishment of Horizon Europe ERA project consortia. Participants will create profiles, including search terms based on the ERA call titles of 2026 (please refer to the WP Draft). Participation in this event is free of charge, and registration is mandatory.
All information related to the brokerage event can be found on this webpage.
The European Commission Info Day for applicants about the ERA calls in the WIDERA Work Programme 2026-2027, Destination “Reforming and enhancing the European research and innovation system” will be held online on 11 December 2025. More information can be found in this announcement.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
